版本:
中国

BRIEF-Esperion reports Q1 net loss per common share $1.80

May 4 Esperion Therapeutics Inc

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

* Esperion Therapeutics Inc - esperion expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million

* Qtrly net loss per common share $1.80 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐